Just One Year Since Launch, CBD IV Infusions Have Exploded in Popularity. SACRAMENTO, Calif. , Aug.
21, 2024 /PRNewswire/ -- Pico IV, pioneers of the world's first CBD IV therapy, are continuing to innovate, expand their offerings and increase accessibility. In just one year since launch, CBD IV infusions went from being in a handful of IV therapy clinics in California to over 200 clinics in almost all 50 states. In that time, over 15,000 doses of CBD have been shipped, leading to thousands of satisfied customers.
The launch of this innovative product was covered in an extensive article in Forbes . Despite the strong market desire for intravenous CBD (aka cannabidiol) and other cannabinoids, no one had previously been able to create a CBD or cannabinoid product that was safe for intravenous use. This is because the particle size is too large to fit through a sterile filter.
Even with the recent advent of nano-technology that allowed cannabinoid particles to be reduced to the size of a nanometer, making it water soluble, it still fell short of the size needed for a sterile filtration process. "We've been blown away by the market response to CBD IV infusions," said Joe Young , CEO of Pico IV. "Users are sharing transformative stories, and we're witnessing firsthand how CBD, delivered intravenously, can make a profound impact.
Pico IV is proud to lead this innovation in the IV therapy industry and we are thrilled to witness just how much we've grown." Miles Terry , Chief Science.